EDURANT 96-Week Phase 3 Safety and Efficacy Data Presented at International AIDS Society ConferenceTuesday, July 19, 2011 @ 7:30AMJanssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT⢠tablets versus efavirenz in antiretroviral treatment-naive, HIV-1-infected adults.
SPONSORED POST: When in Rome…Don’t Do As the Tourists DoTuesday, July 19, 2011 @ 7:28AMYou’ve just left the Coliseum and you’re now on the Spanish Steps watching motorcycles and Vespas zoom down narrow side streets. Locals gesture so intently that for a second you wonder if sign language is the lingua franca.
Global Hotel Alliance Enters Italy; The Lungarno Collection Becomes Its Latest MemberTuesday, July 19, 2011 @ 7:25AMGlobal Hotel Alliance is delighted to welcome the Lungarno Collection as its latest member, as the rapidly-growing alliance now extends its reach into Italy.
Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call ...Tuesday, July 19, 2011 @ 7:14AM( International AIDS Society ) Researchers speaking in the second plenary session of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) have today provided insights into the future direction of HIV/AIDS policy making and alerted delegates to the challenges that developing countries continue to face in the delivery of large- scale antiretroviral therapy coverage.
Summit to hear Greek debt optionsTuesday, July 19, 2011 @ 6:20AMA tax on euro zone banks and cheaper, longer-dated official loans are the least risky way to provide extra funding for debt-stricken Greece, a confidential paper drafted ahead of a European summit showed today.